I. MODIFIED AGREEMENTS | ||||
Biotech Co.* (Country/Symbol) | Biotech Co.* (Country/Symbol) | Change from original agreement | Disclosed Funding (M) | Terms/Details (Date) |
| | ||||
Alliance | Inhale Thera- | Expanded agreement regarding the Pulmo-Sphere particle and particle-processing technology | ND | As a result of the supplemental agreement, Inhale paid Alliance $5.25M in exchange for rights beyond inhaleable applications and other considerations (3/20) |
Aurora | Allergan Inc. | Expanded agreement to work on G protein-coupled receptor targets to develop drug candidates | ND | Aurora will develop and screen functional cell-based assays using its Biosensor cell lines and GeneBLAzer beta-lactamase reporter gene technology to seek GPCR targets; Aurora will receive an up-front payment, and has the potential for research and development milestones, as well as royalties (1/4) |
Celera | Maxim Pharma- | Expanded collaborative research and license agreement to identify and develop small-molecule compounds for certain cancers | ND | Maxim will use its screening assay to evaluate 300,000 additional compounds from Celera's libraries for the purpose of identifying compounds that can induce apoptosis in certain cancer cells (3/18) |
Centocor Inc. | MorphoSys | Expanded agreement in which Centocor increased its funded research at MorphoSys and ordered AutoCAL | ND | The original agreement, signed in December 2000, focuses on the generation of human antibodies in therapeutic and genomics research applications; Centocor received an option for up to 30 therapeutic target molecules against which MorphoSys will make optimized fully human antibodies using HuCAL (3/25) |
Cetek Corp.* | Cubist Pharma- | Expanded research agreement that leverages both companies' expertise in natural products drug discovery to identify novel compounds for the treatment of infectious diseases | ND | Cetek will apply its technologies in natural extract screening and fractionation to identify novel compounds in Cubist's NatChem library (1/31) |
Hybrigen Inc.* | Bionomics Ltd. | Expanded collaboration to discover drug targets to include a novel target identified by Bionomics in its angiogenesis project | ND | The collaboration follows the initial drug target discovery program based on multiple genes identified and patented by Bionomics from its breast cancer project; the companies will co-own the drug targets developed in the program and intend to form a new entity to commercialize discoveries made (1/30) |
Interleukin | Genome | Expanded inflammation research program to include the discovery of novel and proprietary SNPs of the TNF-alpha gene to provide the high-density SNP identification of the gene | ND | Genome Therapeutics will use its GenomeVision Services business; financial terms were not disclosed (1/23) |
MorphoSys AG | Biogen Inc. | Expanded collaboration granting Biogen access to MorphoSys' new HuCAL Gold library for use in Biogen's functional genomics programs | ND | The agreement includes an option for Biogen to develop selected antibodies as therapeutics; MorphoSys will receive additional funded research and licensing payments (1/8) |
II. TERMINATED AGREEMENTS | ||||
Amgen Inc. | Bioject Medical | Terminated agreement for Iject and B2000 devices development | ND | Amgen elected not to pursue continued development of the two needle-free drug delivery systems in two undisclosed indications, but it would not disclose the reasons for the decision (2/27) |
Cell Genesys | GPC Biotech | Discontinued research collaboration and license agreement for p27/p16 gene therapy for cancer and cardiovascular disease | ND | Cell Genesys decided to reprioritize its preclinical programs, which resulted in the decision (3/21) |
Peregrine | Oxigene Inc. | Terminated joint venture, Arcus Therapeutics LLC, which was focused on development of anticancer compounds | $2 | Peregrine will pay Oxigene $2M to reacquire rights and interest to the vascular targeting platform it contributed to the joint venture; Oxigene also will reacquire rights and interest to its technology (3/1) |
| | ||||
Notes: | ||||
# The information in the chart does not cover agricultural agreements. | ||||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market. | ||||
ND = Not disclosed, reported and/or available. | ||||
ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange | ||||
